Mr. Mel Khan Dean
CEO and Managing Director at ALS Limited
Replay available
ALS Limited (ASX: ALQ) Q4 2026 earnings conference call, held 2026-05-18. Replay captured from the company's public earnings webcast.

CEO and Managing Director at ALS Limited
Chief Financial Officer at ALS Limited
at Macquarie
at MST Pharmaceuticals
at Morgan
at Jardan Australia
at UBS
at Bank of America
at RBC
at Goldman Sachs
Good day, and thank you for standing by. Welcome to ALS Limited FY twenty six results briefing. At this time, all participants are in a listen only mode. After the speaker's presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to turn the call over to your first speaker today, Mr. Mel Khan Dean, CEO and Managing Director. Thank you. Please go ahead. Thanks, Desmond, and good morning, and thank you, everyone, for joining us today. It's been a very strong year for Erez, and we've delivered record results, reflecting our ability to achieve strong growth while staying disciplined on margin performance, cash generation and capital allocation. As always, I'm joined by Stuart Hadron, our Chief Financial Officer. We'll speak for around thirty minutes, and then we will open for questions. Four years ago, we set ourselves ambitious fiscal year 'twenty seven targets. I'm pleased to report that we have achieved these targets twelve months early while refining our strategy and focus for the future. What's most pleasing is that we achieved the fiscal year 'twenty seven plan primarily through strong organic growth. Fiscal year 'twenty six revenue was $3,320,000,000 up 10.7%, with strong organic growth of 8.4% at the top end of our guided range, reflecting the breadth of our global operations. Underlying EBIT of $599,000,000 up 19.3%, with EBIT margin accelerating by 129 basis points to 18%. But excluding recent acquisitions, the legacy underlying EBIT margin was 19.8%. Underlying NPAT was up by 25.8% to $381,200,000 a record result for this company. These results for ALS reflects the work of more than 23,000 people across our global network. So I want to acknowledge that upfront, because this was a ...